Laia Bernad
A5072153384- SARS-CoV-2 and COVID-19 Research
- vaccines and immunoinformatics approaches
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
IrsiCaixa
2024-2025
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of PHH-1V adjuvanted recombinant vaccine as heterologous booster against homologous with BNT162b2. Interim results demonstrated strong humoral cellular immune response SARS-CoV-2 Wuhan-Hu-1 strain Beta, Delta, Omicron BA.1 variants up to day 98 post-dosing. Here we report that these responses are sustained 6 months, including in...
Summary The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial to compare the immunogenicity and safety of heterologous booster with PHH-1V adjuvanted recombinant vaccine versus homologous mRNA vaccine. Interim results showed strong humoral cellular immune response against SARS-CoV-2 Wuhan-Hu-1 strain Beta, Delta, Omicron BA.1 variants up day 98 after dosing. Here we report that these responses dosing are sustained 6 months....
Abstract Background Phase IIb HIPRA-HH-2 study results showed that PHH-1V as first booster dose elicited a strong and sustained neutralising antibody response against various SARS-CoV-2 variants. Here, we report the safety immunogenicity of fourth most prevalent Omicron variants in Spain. Methods The open-label extension ( NCT05142553 ) evaluated subjects aged ≥18 years followed for 6 months. Subjects received 6–12 months after previous regime either two doses BNT162b2 plus third (Cohort 1)...
Abstract Background Global COVID-19 vaccination adapts to protect populations from emerging variants. This communication presents interim findings the new Omicron XBB adapted PHH-1V81 vaccine compared a mRNA against and JN.1 SARS-CoV-2 strains. Methods In Phase IIb/III pivotal trial, adults previously vaccinated with primary scheme at least one booster dose of an EU-approved randomly received either or BNT162b2 XBB.1.5 as single dose. The efficacy endpoint assessed neutralisation titers...
Abstract In this phase III, open label, single arm, multicenter clinical study, we report safety, tolerability and immunogenicity of PHH-1V as a booster dose in subjects primary vaccinated against COVID-19 with the BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S vaccines, without previous infection. A total 2661 were included study vaccine. Most treatment-emergent adverse events (TEAE) solicited local systemic reactions grade 1 (58.70%) 2 (27.58%) intensity, being most frequently reported...
(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings the new Omicron XBB.1.16-adapted PHH-1V81 protein-based vaccine compared an XBB.1.5-adapted mRNA against various acute respiratory syndrome 2 (SARS-CoV-2) strains. (2) Methods: In a Phase IIb/III pivotal trial, adults previously vaccinated with primary scheme and at least one booster dose of EU-approved randomly received either or...